The $423M cash pile looks like a floor — strip the claims against it and barely $50M survives.

• $417M of convertible notes mature in 2027. The strike sits far above $8.93, so refinancing — not conversion — is the path. The window opens late 2026 and will be negotiated from weakness.
• $47M of cash is already restricted by a PNNL surety bond locked until roughly 2029. Usable cash drops to about $375M before any FY26 spend.
• FY26 cash-burn guide is $125–150M, with a $54M annual excess-lease drag baked into opex. After one year of burn and honoring the converts, unencumbered cash compresses to a low-double-digit-million figure.

Revenue is shrinking faster than the cash burn, and Q1 just printed the worst quarter since 2020.

Cell Engineering — the segment that is supposed to be the business — has never produced a profitable year in seven years of public disclosure. The lower cash burn is bought with deferred maintenance: capex collapsed to $7.7M last year, just 0.13× depreciation. On the Q4 call management withdrew FY26 revenue guidance entirely and replaced it with a cash-burn target.

When customers walked away, the accounting recognized the unspent contracts as revenue.

• 22% of FY24 revenue — $49.9M — came from non-cash deferred-revenue releases on terminated programs (Motif $45.4M plus a related-party $4.5M). FY25 added another $7.5M from BiomEdit. The customer is gone; the GAAP line item arrived anyway.
• Three Programs KPIs were discontinued in Q4 FY24 — the exact quarter they inflected down. New Programs had already dropped from 78 (FY23) to 52 (FY24). Disclosure stopped before the next decline could be measured.
• $17.75M securities settlement in Dec-2024 (Bernstein v. Ginkgo, N.D. Cal., final approval 13-Dec-2024) and a $4.125M insurance-funded derivative settlement noticed in Aug-2025 with three-year corporate-governance reforms. The SEC inquiry from October 2021 was closed with no recommendation of enforcement per the FY2025 10-K; the DOJ informal inquiry from Nov-2021 has no public update.

Weeks after FY25 mega-grants vested, the founder circle sold into a 52-week low.

• April 9–10, 2026: coordinated Form 4 sales at $6.40–6.93 from CEO Kelly (~$1.37M on 206,782 shares) and from the co-founder/spouse pair Shetty and Canton (~$978K of jointly-held shares, reported on each spouse's Form 4). CFO Coen separately sold ~$215K on April 13–17. Standard analyst datasets did not flag the cluster.
• The trigger was the vest. Kelly's stock-award compensation jumped from $0 in FY23 to $5.45M in FY25; Shetty's went from $0 to $3.22M. Vest, then sell into a 52-week low. Stock-based comp ran roughly 48% of FY25 revenue.
• Dual-class control compounds the alignment problem. Founders plus co-founder Che hold roughly 58% of the vote on under 20% of the economics. Independent Chair Shyam Sankar leaves at the 2026 AGM. Board member Sri Kosuri runs Octant Bio — a competing private synthetic-biology firm — with no public recusal policy.

Every named TechBio peer grew revenue in FY25. DNA shrank 32% and is alone in contraction.

Schrödinger and Twist are the proof points that a TechBio platform can self-fund and can scale gross margin from a starting base similar to Ginkgo's. Ginkgo has done neither. Ten of the top 20–30 pharma have touched the platform per management, but no top-10 commercial Datapoints anchor has been disclosed — the slide from research-service revenue to durable repeat-revenue has not been demonstrated.